CARA Therapeutics' GAAP loss for 6M 2021 was $54.046 million, up 0.1% from $53.99 million in the prior year. Revenue declined 6.9 times to $1.935 million from $13.727 million a year earlier.
CARA Therapeutics' GAAP loss for 6M 2021 was $54.046 million, up 0.1% from $53.99 million in the prior year. Revenue declined 6.9 times to $1.935 million from $13.727 million a year earlier. 
ir.caratherapeutics.com
English (US) 